UBS Group reiterated their buy rating on shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) in a research note issued to investors on Wednesday morning, The Fly reports.
Several other research analysts have also issued reports on the company. Sanford C. Bernstein assumed coverage on Roche Holdings AG Basel in a research report on Monday, July 13th. They issued an outperform rating on the stock. Barclays restated an overweight rating on shares of Roche Holdings AG Basel in a research report on Friday, May 15th. Morgan Stanley reiterated an overweight rating on shares of Roche Holdings AG Basel in a report on Wednesday. AlphaValue upgraded Roche Holdings AG Basel to a reduce rating in a report on Friday, July 3rd. Finally, HSBC upgraded Roche Holdings AG Basel from a reduce rating to a hold rating in a report on Thursday, April 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $48.00.
OTCMKTS RHHBY opened at $43.10 on Wednesday. Roche Holdings AG Basel has a 52 week low of $33.30 and a 52 week high of $46.63. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.04 and a current ratio of 1.30. The stock has a market capitalization of $295.17 billion, a P/E ratio of 16.97, a price-to-earnings-growth ratio of 3.01 and a beta of 0.37. The stock has a fifty day moving average of $44.21 and a 200-day moving average of $42.63.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Recommended Story: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.